Atherosclerotic cardiovascular disease (ACD) in renal transplant patients (RTP) is the main cause of death, roughly 50–60%. In nondiabetic RTP the incidence of death because of ischemic heart disease is approximately six times higher, and in diabetic RTP 20 times higher, than in the general population.
Risk factors for the development of vascular disease in RTP include diabetes, hypertension, hyperlipidemia, smoking, and immunosuppressive regimens. Hyperlipidemia is a well-known risk factor for ACD, especially the increments of total cholesterol (TC) and low-density lipoprotein (LDLc). Moreover hyperlipidemia is involved in the development of chronic allograft rejection. Pathogenesis of hyperlipidemia include cyclosporine, renal dysfunction, diabetes, proteinuria, prednisone dose, obesity, age and gender, and the use of certain beta-blocking or diuretic drugs. The HMG-CoA reductase inhibitors are the most powerful drugs for lowering LDLc and TC in hyperlipidemic patients.
We have studied the effect of fluvastatin (FV), a HMG-CoA reductase inhibitor, on hypercholesterolemia of RTP.
CITATION Transplant Proc. 1999 Sep;31(6):2326-7